Added to YB: 2026-04-09
Pitch date: 2026-04-01
CPH.TO [neutral]
Cipher Pharmaceuticals Inc.
-0.5%
current return
Author Info
Petty Cash shares microcap investing ideas (mainly in Canada) in their newsletter. Sign up for the newsletter.
Company Info
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
Market Cap
CAD 347.8M
Pitch Price
CAD 18.13
Price Target
N/A
Dividend
N/A
EV/EBITDA
14.36
P/E
13.09
EV/Sales
6.85
Sector
Pharmaceuticals
Category
special_situation
Petty Cash Q1 2026 Portfolio Update - Cipher Pharmaceuticals Inc.
CPH.TO (holding update): +21.2% in Q1 2026, range-bound since mid-2024 Natroba acquisition announcement. Author maintains large position, expects strong year ahead. Stock found support after initial acquisition excitement faded.
Read full article (1 min)